Halozyme Therapeutics, Inc. $HALO Position Raised by Thrivent Financial for Lutherans

Thrivent Financial for Lutherans boosted its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 222.5% in the third quarter, HoldingsChannel.com reports. The firm owned 93,555 shares of the biopharmaceutical company’s stock after purchasing an additional 64,542 shares during the quarter. Thrivent Financial for Lutherans’ holdings in Halozyme Therapeutics were worth $6,862,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of HALO. CWM LLC boosted its position in shares of Halozyme Therapeutics by 2,136.0% in the 3rd quarter. CWM LLC now owns 23,881 shares of the biopharmaceutical company’s stock valued at $1,751,000 after purchasing an additional 22,813 shares during the period. Arbor Investment Advisors LLC purchased a new stake in Halozyme Therapeutics during the third quarter valued at about $1,316,000. Monument Capital Management purchased a new stake in Halozyme Therapeutics during the third quarter valued at about $2,015,000. Pacer Advisors Inc. boosted its holdings in shares of Halozyme Therapeutics by 2,054.7% in the third quarter. Pacer Advisors Inc. now owns 478,874 shares of the biopharmaceutical company’s stock worth $35,121,000 after buying an additional 456,649 shares during the period. Finally, Cardinal Capital Management purchased a new position in shares of Halozyme Therapeutics in the third quarter worth approximately $1,303,000. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Halozyme Therapeutics

In other news, CEO Helen Torley sold 20,000 shares of the firm’s stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $76.12, for a total transaction of $1,522,400.00. Following the transaction, the chief executive officer owned 708,719 shares in the company, valued at approximately $53,947,690.28. This trade represents a 2.74% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Bernadette Connaughton sold 2,000 shares of Halozyme Therapeutics stock in a transaction on Monday, November 10th. The shares were sold at an average price of $68.48, for a total transaction of $136,960.00. Following the completion of the sale, the director directly owned 42,952 shares of the company’s stock, valued at approximately $2,941,352.96. The trade was a 4.45% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 71,398 shares of company stock worth $5,170,152. Insiders own 2.40% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have issued reports on HALO shares. Morgan Stanley cut their target price on shares of Halozyme Therapeutics from $80.00 to $79.00 and set an “overweight” rating on the stock in a research note on Monday, October 20th. The Goldman Sachs Group reissued a “sell” rating and issued a $56.00 price objective on shares of Halozyme Therapeutics in a research note on Thursday, December 4th. HC Wainwright restated a “buy” rating on shares of Halozyme Therapeutics in a research report on Thursday, January 29th. Weiss Ratings cut Halozyme Therapeutics from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, January 26th. Finally, Leerink Partners raised shares of Halozyme Therapeutics from an “underperform” rating to a “market perform” rating and set a $70.00 price target for the company in a research report on Tuesday, October 14th. Seven research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Halozyme Therapeutics currently has an average rating of “Hold” and an average target price of $78.80.

Halozyme Therapeutics Stock Performance

Shares of HALO stock opened at $78.42 on Friday. Halozyme Therapeutics, Inc. has a fifty-two week low of $47.50 and a fifty-two week high of $79.50. The stock’s 50-day moving average is $69.23 and its two-hundred day moving average is $68.91. The company has a debt-to-equity ratio of 1.59, a current ratio of 1.59 and a quick ratio of 1.37. The firm has a market cap of $9.22 billion, a P/E ratio of 16.51, a PEG ratio of 0.32 and a beta of 0.97.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Monday, November 3rd. The biopharmaceutical company reported $1.72 EPS for the quarter, beating the consensus estimate of $1.63 by $0.09. Halozyme Therapeutics had a return on equity of 156.95% and a net margin of 47.91%.The business had revenue of $354.26 million during the quarter, compared to analysts’ expectations of $339.18 million. During the same quarter in the previous year, the business posted $1.27 EPS. The firm’s quarterly revenue was up 22.1% compared to the same quarter last year. Analysts predict that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.